CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Icotinib

埃克替尼 杂质对照品Icotinib Impurities

28 个杂质条目28 impurity entries

本页汇总 埃克替尼 的 28 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 28 impurity reference standards of Icotinib. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 埃克替尼(Icotinib)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsA fully validated method for simultaneous determination of icotinib, osimertinib, gefitinib and O-desmethyl gefitinib in human plasma using UPLC-MS/MS for therapeutic drug monitoring
    Journal of pharmaceutical and biomedical analysis · 2023 · Li B et al.  ·  PMID 37713984  ·  DOI
  2. 分析方法Analytical MethodsSimultaneous determination of icotinib, osimertinib, aumolertinib, and anlotinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS
    Journal of pharmaceutical and biomedical analysis · 2024 · Xu Y et al.  ·  PMID 39214029  ·  DOI
  3. 分析方法Analytical MethodsValidation of an LC-MS/MS method for simultaneous determination of icotinib and its four major circulating metabolites in human plasma and its application in a pharmacokinetic study
    Biomedical chromatography : BMC · 2018 · Xiao Y et al.  ·  PMID 29975793  ·  DOI
  4. 分析方法Analytical MethodsQuantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2009 · Liu D et al.  ·  PMID 19833564  ·  DOI
  5. 分析方法Analytical MethodsMetabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry
    Rapid communications in mass spectrometry : RCM · 2011 · Liu D et al.  ·  PMID 21732454  ·  DOI

埃克替尼 —— 原料药与杂质对照品Icotinib — drug substance & impurities

共 28 个条目(含原料药本体)28 items incl. the drug substance
Icotinib Monomer-d4 structure
—
埃克替尼-d4Icotinib Monomer-d4
Icotinib Monomer-d4
CAS No.1567366-82-8
Chemical FormulaC22H17D4N3O4
Purity>95%询价On request
Icotinib Monomer structure
—
埃克替尼 单体Icotinib Monomer
Icotinib Monomer
CAS No.610798-31-7
Chemical FormulaC22H21N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 1 structure
1
埃克替尼杂质1Icotinib Impurity 1
Icotinib Impurity 1
CAS No.1058651-74-3
Chemical FormulaC22H21N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 2 structure
2
埃克替尼杂质2Icotinib Impurity 2
Icotinib Impurity 2
CAS No.1643673-64-6
Chemical FormulaC22H20ClN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 3 structure
3
埃克替尼杂质3Icotinib Impurity 3
Icotinib Impurity 3
CAS No.1643673-51-1
Chemical FormulaC22H20FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 4 structure
4
埃克替尼杂质4Icotinib Impurity 4
Icotinib Impurity 4
CAS No.1058651-82-3
Chemical FormulaC28H29N3O11
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 5 structure
5
埃克替尼杂质5Icotinib Impurity 5
Icotinib Impurity 5
CAS No.2249867-59-0
Chemical FormulaC18H13N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 6 structure
6
埃克替尼杂质6Icotinib Impurity 6
Icotinib Impurity 6
CAS No.1869913-77-8
Chemical FormulaC20H21N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 7 structure
7
埃克替尼杂质7Icotinib Impurity 7
Icotinib Impurity 7
CAS No.2249867-60-3
Chemical FormulaC19H15N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 8 structure
8
埃克替尼杂质8Icotinib Impurity 8
Icotinib Impurity 8
CAS No.153437-34-4
Chemical FormulaC17H15N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 9 structure
9
埃克替尼杂质9Icotinib Impurity 9
Icotinib Impurity 9
CAS No.412930-46-2
Chemical FormulaC18H17N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 10 structure
10
埃克替尼杂质10Icotinib Impurity 10
Icotinib Impurity 10
CAS No.2376901-56-1
Chemical FormulaC20H21N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 11 structure
11
埃克替尼杂质11Icotinib Impurity 11
Icotinib Impurity 11
CAS No.2305154-39-4
Chemical FormulaC17H12N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 12 structure
12
埃克替尼杂质12Icotinib Impurity 12
Icotinib Impurity 12
CAS No.610798-26-0
Chemical FormulaC20H20ClN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 13 structure
13
埃克替尼杂质13Icotinib Impurity 13
Icotinib Impurity 13
CAS No.610798-18-0
Chemical FormulaC20H20BrN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 14 structure
14
埃克替尼杂质14Icotinib Impurity 14
Icotinib Impurity 14
CAS No.1887066-23-0
Chemical FormulaC22H25N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 15 structure
15
埃克替尼杂质15Icotinib Impurity 15
Icotinib Impurity 15
CAS No.1887066-21-8
Chemical FormulaC20H21N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 16 structure
16
埃克替尼杂质16Icotinib Impurity 16
Icotinib Impurity 16
CAS No.1708935-17-4
Chemical FormulaC19H15N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 17 structure
17
埃克替尼杂质17Icotinib Impurity 17
Icotinib Impurity 17
CAS No.2376901-55-0
Chemical FormulaC20H21N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 18 structure
18
埃克替尼杂质18Icotinib Impurity 18
Icotinib Impurity 18
CAS No.1318600-04-2
Chemical FormulaC22H23N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 19 structure
19
埃克替尼杂质19Icotinib Impurity 19
Icotinib Impurity 19
CAS No.1318600-10-0
Chemical FormulaC22H25N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 20 structure
20
埃克替尼杂质20Icotinib Impurity 20
Icotinib Impurity 20
CAS No.1318600-06-4
Chemical FormulaC22H23N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 21 structure
21
埃克替尼杂质21Icotinib Impurity 21
Icotinib Impurity 21
CAS No.1708935-20-9
Chemical FormulaC21H19N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 22 structure
22
埃克替尼杂质22Icotinib Impurity 22
Icotinib Impurity 22
CAS No.1207868-20-9
Chemical FormulaC18H17N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 23 structure
23
埃克替尼杂质23Icotinib Impurity 23
Icotinib Impurity 23
CAS No.1887066-25-2
Chemical FormulaC24H29N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 26 structure
26
埃克替尼杂质26Icotinib Impurity 26
Icotinib Impurity 26
CAS No.1403772-39-3
Chemical FormulaC14H19NO6
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 27 structure
27
埃克替尼杂质27Icotinib Impurity 27
Icotinib Impurity 27
CAS No.1204313-57-4
Chemical FormulaC14H16N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Icotinib Impurity 28 structure
28
埃克替尼杂质28Icotinib Impurity 28
Icotinib Impurity 28
CAS No.1204313-58-5
Chemical FormulaC14H15ClN2O4
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

埃克替尼 —— 研究文献与合成路线Icotinib — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 埃克替尼 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Icotinib. Titles link to the original records; copyright remains with the authors and publishers.

合成路线文献Synthetic-route papers

  1. Design, synthesis and antitumor activity of icotinib derivatives
    Mao L, Sun G, Zhao J, et al. · Bioorganic chemistry · 2020
  2. Synthesis and preliminary evaluation of 18F-icotinib for EGFR-targeted PET imaging of lung cancer
    Lu X, Wang C, Li X, et al. · Bioorganic & medicinal chemistry · 2019
  3. Icotinib Hydrochloride, Synthesis, Crystalline Forms, Pharmaceutical Compositions, and Uses Thereof
    WANG YINXIANG, XIE GUOJIAN, DING LIEMING, et al. · 2011

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

埃克替尼 杂质谱研究要点Icotinib — impurity profiling notes

下面这些是拿到 埃克替尼 的 28 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 28 impurity entries for Icotinib, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances